1. Home
  2. BDSX vs SNTI Comparison

BDSX vs SNTI Comparison

Compare BDSX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.85

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$1.31

Market Cap

53.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
SNTI
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.0M
53.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BDSX
SNTI
Price
$7.85
$1.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$32.50
$9.00
AVG Volume (30 Days)
62.6K
4.1M
Earning Date
11-03-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$80,173,000.00
N/A
Revenue This Year
$20.75
N/A
Revenue Next Year
$25.05
$150.00
P/E Ratio
N/A
N/A
Revenue Growth
22.29
N/A
52 Week Low
$3.44
$1.26
52 Week High
$32.20
$5.96

Technical Indicators

Market Signals
Indicator
BDSX
SNTI
Relative Strength Index (RSI) 52.12 34.89
Support Level $7.77 $1.34
Resistance Level $8.38 $2.88
Average True Range (ATR) 0.57 0.25
MACD -0.01 -0.09
Stochastic Oscillator 60.38 2.48

Price Performance

Historical Comparison
BDSX
SNTI

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Share on Social Networks: